ALICE

Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. NBCG16, PI: Jon Amund Kyte.

Bay BC Ra233 Study B (17096)

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases. PI: Bjørn Naume.

BROCADE 3

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. The AbbVie-study M12-895, PI: Hans Petter Eikesdal.

COMPLEEMENT-1

COMPLEEMENT-1: An open-label, multicenter, Phase IIIbstudy to assess the safety and efficacy of ribociclib(LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.  PI: Louay Garabet. Forventet oppstart tidlig 2018.

I-BCT

Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting. PI: Olav Engebråten.

ICON

ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer. PI: Jon Amund Kyte. Forventet oppstart tidlig 2018.

LYTIX

A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab. PI: Pål Fr. Brunsvig.

Neo-BCT-2

Breast conserving surgery (BCT) after neoadjuvant therapy for large primary breast cancer (T2-T3) with infavourable tumor-to-breast size ratio(NEO‐BCT‐2). Kun aktuell ved inklusjon i I-BCT studien. PI: Helle Skjerven.

NEOLETEXE

Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.

PETREMAC

PErsonalized TREatment of high-risk MAmmary Cancer – the PETREMAC Trial. Positive Trial. NBCG15, PI: Hans Petter Eikesdal.

POSITIVE studien

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer. PI: Anna Sætersdal.

Skagen Trial I

Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. PI: Ingvil Mjaaland.